Efficient tumor targeting by anaerobic butyrate-producing bacteria

Medical Hypotheses

Volumn 80, Issue 5, 2013, Pages 675-678

  Tirandaz, Hassan ^a   Mohammadi, Ebrahim ^b,c  

^a RESEARCH INSTITUTE OF PETROLEUM INDUSTRY RIPI   (Iran)

^b KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID;

ANAEROBIC BACTERIUM; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL HYPOXIA; DRUG BIOAVAILABILITY; HUMAN; HYPOTHESIS; TUMOR CELL;

BACTERIA, ANAEROBIC; BIOLOGICAL AGENTS; BUTYRIC ACID; HUMANS; NEOPLASMS;

BACTERIA (MICROORGANISMS);

EID: 84875606173     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.01.024     Document Type: Article

References (47)

1. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4(6):437-447.
2. Barbe S., Van Mellaert L., Anne J. The use of clostridial spores for cancer treatment. J Appl Microbiol 2006, 101(3):571-578.
3. Ryan R.M., Green J., Lewis C.E. Use of bacteria in anti-cancer therapies. Bioessays 2006, 28(1):84-94.
4. Parker R.C., Plummer H.C., Siebenmann C.O., Chapman M.G. Effect of histolyticus infection and toxin on transplantable mouse tumors. Proc Soc Exp Biol Med 1947, 66(2):461-467.
5. Malmgren R.A., Flanigan C.C. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res 1955, 15(7):473-478.
6. Forbes N.S. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 2010, 10(11):785-794.
7. Baban C.K., Cronin M., O'Hanlon D., O'Sullivan G.C., Tangney M. Bacteria as vectors for gene therapy of cancer. Bioeng Bugs 2010, 1(6):385-394.
8. Yu H. Bacteria-mediated disease therapy. Appl Microbiol Biotechnol 2011, 92(6):1107-1113.
9. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5(9):769-784.
10. Fraga M.F., Esteller M. Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle 2005, 4(10):1377-1381.
11. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000, 92(15):1210-1216.
12. Riggs M.G., Whittaker R.G., Neumann J.R., Ingram V.M. N-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977, 268(5619):462-464.
13. Coradini D., Zorzet S., Rossin R., et al. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res 2004, 10(14):4822-4830.
14. Chen Z., Clark S., Birkeland M., et al. Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett 2002, 188(1-2):127-140.
15. Heerdt B.G., Houston M.A., Augenlicht L.H. Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell Growth Differ 1997, 8(5):523-532.
16. Louis M., Rosato R.R., Brault L., et al. The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress. Int J Oncol 2004, 25(6):1701-1711.
17. Wang Y.F., Chen N.S., Chung Y.P., Chang L.H., Chiou Y.H., Chen C.Y. Sodium butyrate induces apoptosis and cell cycle arrest in primary effusion lymphoma cells independently of oxidative stress and p21(CIP1/WAF1) induction. Mol Cell Biochem 2006, 285(1-2):51-59.
18. Zhang Y., Zhou L., Bao Y.L., et al. Butyrate induces cell apoptosis through activation of JNK MAP kinase pathway in human colon cancer RKO cells. Chem Biol Interact 2010, 185(3):174-181.
19. Sun S., Li W., Zhang H., et al. Requirement for store-operated calcium entry in sodium butyrate-induced apoptosis in human colon cancer cells. Biosci Rep 2012, 32(1):83-90.
20. Dyer E.S., Paulsen M.T., Markwart S.M., Goh M., Livant D.L., Ljungman M. Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay. Int J Cancer 2002, 101(5):496-499.
21. Kim S.H., Kim K.W., Jeong J.W. Inhibition of hypoxia-induced angiogenesis by sodium butyrate, a histone deacetylase inhibitor, through hypoxia-inducible factor-1alpha suppression. Oncol Rep 2007, 17(4):793-797.
22. Sawa H., Murakami H., Ohshima Y., et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol 2002, 19(2):77-81.
23. Pellizzaro C., Coradini D., Daniotti A., Abolafio G., Daidone M.G. Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines. Int J Cancer 2001, 91(5):654-657.
24. Zhou Q., Dalgard C.L., Wynder C., Doughty M.L. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells. BMC Neurosci 2011, 12:50.
25. Jeng J.H., Kuo M.Y., Lee P.H. Toxic and metabolic effect of sodium butyrate on SAS tongue cancer cells: role of cell cycle deregulation and redox changes. Toxicology 2006, 223(3):235-247.
26. Zhang C., Yang H., Yang F., Ma Y. Current progress on butyric acid production by fermentation. Curr Microbiol 2009, 59(6):656-663.
27. Minton N.P. Clostridia in cancer therapy. Nat Rev Microbiol 2003, 1(3):237-242.
28. Wei J., Ellem K.A., Dunn P., West M.J., Bai C.X., Vogelstein B. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur J Cancer 2007, 43(3):490-496.
29. Schmidt W., Fabricius E.M., Schneeweiss U. The tumour-Clostridium phenomenon: 50 years of developmental research (Review). Int J Oncol 2006, 29(6):1479-1492.
30. Zhu Y., Liu X., Yang S.T. Construction and characterization of pta gene-deleted mutant of Clostridium tyrobutyricum for enhanced butyric acid fermentation. Biotechnol Bioeng 2005, 90(2):154-166.
31. Liu X., Zhu Y., Yang S.T. Construction and characterization of ack deleted mutant of Clostridium tyrobutyricum for enhanced butyric acid and hydrogen production. Biotechnol Prog 2006, 22(5):1265-1275.
32. Ohkawara S., Furuya H., Nagashima K., Asanuma N., Hino T. Oral administration of butyrivibrio fibrisolvens, a butyrate-producing bacterium, decreases the formation of aberrant crypt foci in the colon and rectum of mice. J Nutr 2005, 135(12):2878-2883.
33. Codd R., Braich N., Liu J., Soe C.Z., Pakchung A.A. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. Int J Biochem Cell Biol 2009, 41(4):736-739.
34. Patyar S., Joshi R., Byrav D.S., Prakash A., Medhi B., Das B.K. Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci 2010, 17(1):21.
35. Louis P., Flint H.J. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 2009, 294(1):1-8.
36. Low K.B., Ittensohn M., Le T., et al. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 1999, 17(1):37-41.
37. Dang L.H., Bettegowda C., Huso D.L., Kinzler K.W., Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001, 98(26):15155-15160.
38. Bettegowda C., Dang L.H., Abrams R., et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci USA 2003, 100(25):15083-15088.
39. Daniel P., Brazier M., Cerutti I. Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. Clin Chim Acta 1989, 181(3):255-263.
40. Miller A.A., Kurschel E., Osieka R., Schmidt C.G. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987, 23(9):1283-1287.
41. Lee C.H. Engineering bacteria toward tumor targeting for cancer treatment: current state and perspectives. Appl Microbiol Biotechnol 2012, 93(2):517-523.
42. Zhao M., Yang M., LiX M., et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 2005, 102:755-760.
43. Hayashi K., Zhao M., Yamauchi K., et al. Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem 2009, 106(6):992-998.
44. Jia L.J., Wei D.P., Sun Q.M., Huang Y., Wu Q., Hua Z.C. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models. Cancer Sci 2007, 98(7):1107-1112.
45. Crull K., Bumann D., Weiss S. Influence of infection route and virulence factors on colonization of solid tumors by Salmonella enterica serovar Typhimurium. FEMS Immunol Med Microbiol 2011, 62(1):75-83.
46. Jiang Z.P., Xu P., Wang G.P., Zhao X.L., Chen F.P. Hypothesizing that histone deacetylase inhibitors can be used to reverse multiple drug resistance. Med Hypotheses 2010, 74(1):92-94.
47. Vivier E., Ugolini S., Blaise D., Chabannon C., Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012, 12(4):239-252.